Patients with hereditary angioedema due to C1 esterase inhibitor deficiency (C1-INH-HAE) are at risk for an attack during and after medical procedures; short-term prophylaxis may minimize this risk. This analysis evaluated recombinant C1-INH (rhC1-INH) as short-term prophylaxis prior to dental procedures. METHODS: Patients with angioedema received rhC1-INH prior to dental procedures; angioedema attacks were recorded through 2 days and >2-7 days postprocedure. RESULTS: 29 patients (median age, 44 years [range, 17.5-73.1 years]; 72.4% female; 89.7% HAE type I; median of 17 attacks/year [range, 0-90]) were treated for 37 procedures. More than half (56.8%) of the 37 dental procedures were extractions. A median rhC1-INH prophylactic dose of 3550 IU (range, 2100-4200 IU) was administered a median of 60 minutes prior to the dental procedure. Twenty-five (67.6%) cases had rhC1-INH administered 30-60 minutes preprocedure. Nine (24.3%) cases were also receiving long-term prophylaxis (danazol [n58]; tranexamic acid [n51]). Overall, 97.3% (36/37) of cases did not have an attack within 2 days postprocedure; 91.9% (34/37) during >2-7 days postprocedure. For the 1 attack occurring within 2 days, rhC1-INH (4200 IU; 37.5 IU/kg) was administered 230 minutes preprocedure; the patient experienced mild knee edema and required no treatment. No adverse events were reported. In a retrospective self-control subgroup, 15 (93.8%) of 16 dental procedures (no long-term/short-term prophylaxis preprocedure) were followed by an attack within 2 days after the procedure. CONCLUSIONS: Short-term prophylaxis with rhC1-INH, administered within ;60 minutes before a dental procedure, was efficacious and safe in patients with angioedema/C1-INH-HAE and reduced the risk of an attack postprocedure. (N5125; NCT02586805) . The HELP open-label extension (OLE; NCT02741596) enrolled lanadelumab-treated patients (HELP Study rollover; n5109/113 [96.5%] completers) and lanadelumab-untreated patients (nonrollover; n5103). Here we report interim results (26May2016-1September2017) for rollover and nonrollover patients switching from C1 inhibitor (C1-INH) long-term prophylaxis (LTP) to lanadelumab treatment. METHODS: All patients > _12 years old with HAE type I/II received lanadelumab 300 mg every 2 weeks (q2wks); nonrollover switching patients could receive both C1-INH and lanadelumab to Day 15 (LTP tapering period). The number of investigator-confirmed HAE attacks was reported as monthly attack rates (attacks/4 weeks) and compared with historical rates per 4 weeks for the 3 months preceding HELP (rollover)/ OLE (nonrollover) treatment. RESULTS: Overall, 106/212 patients (50.0%) received prior C1-INH only LTP (53 rollover and 53 nonrollover). Historical median (range) attack rate for all patients using C1-INH was 2.0 (0.0-15.4)/4 weeks. After lanadelumab treatment median (range) attack rate was 0.1 (0.0-4.1)/4 weeks, representing 97.4% median reduction (74.8% mean reduction). Patients without prior LTP use (n587) had median (range) attack rates/4 weeks of 1.8 (0.0-27.6) historically and 0.0 (0.0-4.9) with lanadelumab (100% median reduction; 90.2% mean reduction). Patients switching from other LTP (n519) also experienced attack rate reductions with lanadelumab. CONCLUSIONS: Open-label treatment with lanadelumab 300 mg q2wks led to significant reductions in HAE attack rate compared with 3-month historical experience in patients with and without prior C1-INH LTP use, consistent with findings from the HELP Study.
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